Blood Samples, Liver Metastases, Pancreatic Cancer, Tumor Tissue Biopsy
Conditions
Keywords
Pancreatic cancer, Liver metastases, Tumor tissue biopsy, Blood samples, Xenografts, Murine, Genomic profiling, Circulating biomarkers
Brief summary
This is a feasibility study to perform image-guided liver biopsies in 25 patients who have pancreatic cancer with liver metastasis (cancer in the pancreas that has spread to the liver). This will contribute with samples for the bio-bank (bank of tumors) and develop xenografts (human tumors growing in mice) for further analysis of genes.
Detailed description
This study might bring a better understanding of the metastatic pancreatic cancer and evaluate the differences between the metastatic and the primary pancreatic cancer (the type that does not have metastasis).
Interventions
None listed
Sponsors
University Health Network, Toronto
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Minimum age of 18 years old * Pancreatic cancer with liver metastasis * No contraindication to image-guided biopsy of liver metastasis, including uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine etc) and no significant hepatic dysfunction. * Provide written informed consent * ECOG 0,1 or 2
Exclusion criteria
* Inability to lie supine for more than 30 minutes * ECOG 3 or more * Serious medical risk factors involving any of the major organ systems or including uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine etc) and no significant hepatic dysfunction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with adverse events due to biopsies | up to 2 years | Monitoring adverse events during trial related to biopsies |
| Number of successful xenografts | up to 2 years | determine the take rate or success of establishing xenografts |
| Number of similarities and differences between original patient tumor sample with xenograft sample | up to 2 years | complete histological and molecular comparison of original patient sample with murine xenograft |
| Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival) | up to date of death from any cause | determine the correlation between engraftment rate and clinical data (response to treatment, disease-free survival, overall survival). |
Countries
Canada
Outcome results
None listed